• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞自主的Fas(CD95)/Fas配体相互作用介导T细胞杂交瘤中激活诱导的细胞凋亡。

Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.

作者信息

Brunner T, Mogil R J, LaFace D, Yoo N J, Mahboubi A, Echeverri F, Martin S J, Force W R, Lynch D H, Ware C F

机构信息

Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology, California 92037.

出版信息

Nature. 1995 Feb 2;373(6513):441-4. doi: 10.1038/373441a0.

DOI:10.1038/373441a0
PMID:7530336
Abstract

A number of murine T-cell hybridomas undergo apoptosis within a few hours of activation by specific antigens, mitogens, antibodies against the T-cell antigen receptor, or a combination of phorbol ester and calcium ionophore. This phenomenon has been extensively studied as a model for clonal deletion in the immune system, in which potentially autoreactive T cells eliminate themselves by apoptosis after activation, either in the thymus or in the periphery. Here we show that the Fas/CD95 receptor, which can transduce a potent apoptotic signal when ligand, is rapidly expressed following activation of T-cell hybridomas, as is its functional, membrane-bound ligand. Interference with the ensuing Fas/Fas-ligand interaction inhibits activation-induced apoptosis. Because T-cell receptor ligation can induce apoptosis in a single T hybridoma cell, we suggest that the Fas/Fas-ligand interaction can induce cell death in a cell-autonomous manner.

摘要

许多小鼠T细胞杂交瘤在被特定抗原、有丝分裂原、抗T细胞抗原受体抗体或佛波酯与钙离子载体的组合激活后的几小时内会发生凋亡。这种现象作为免疫系统中克隆缺失的模型已被广泛研究,在该模型中,潜在的自身反应性T细胞在激活后,无论是在胸腺还是在外周,都会通过凋亡消除自身。我们在此表明,Fas/CD95受体在T细胞杂交瘤激活后会迅速表达,其功能性膜结合配体也是如此,当配体存在时,该受体可转导强烈的凋亡信号。干扰随后的Fas/Fas配体相互作用可抑制激活诱导的凋亡。由于T细胞受体连接可在单个T杂交瘤细胞中诱导凋亡,我们认为Fas/Fas配体相互作用可通过细胞自主方式诱导细胞死亡。

相似文献

1
Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas.细胞自主的Fas(CD95)/Fas配体相互作用介导T细胞杂交瘤中激活诱导的细胞凋亡。
Nature. 1995 Feb 2;373(6513):441-4. doi: 10.1038/373441a0.
2
Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.T细胞活化后程序性细胞死亡所需的Fas(CD95)/FasL相互作用。
Nature. 1995 Feb 2;373(6513):444-8. doi: 10.1038/373444a0.
3
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95).由APO-1/(Fas/CD95)介导的自分泌T细胞自杀
Nature. 1995 Feb 2;373(6513):438-41. doi: 10.1038/373438a0.
4
Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis. Activation-induced death can occur without Fas receptor.表面T细胞Fas受体/CD95的调节、体内激活及凋亡。无Fas受体时也可发生激活诱导的死亡。
J Immunol. 1996 Jan 1;156(1):192-200.
5
Bcl-2 blocks glucocorticoid- but not Fas- or activation-induced apoptosis in a T cell hybridoma.Bcl-2可阻断T细胞杂交瘤中糖皮质激素诱导的凋亡,但不能阻断Fas或激活诱导的凋亡。
J Immunol. 1995 Nov 15;155(10):4644-52.
6
Requirement of Fas(CD95), CD45, and CD11a/CD18 in monocyte-dependent apoptosis of human T cells.Fas(CD95)、CD45和CD11a/CD18在人T细胞单核细胞依赖性凋亡中的需求
J Immunol. 1996 Jul 15;157(2):707-13.
7
Apoptosis signaling pathways in normal T cells: differential activity of Bcl-2 and IL-1beta-converting enzyme family protease inhibitors on glucocorticoid- and Fas-mediated cytotoxicity.正常T细胞中的凋亡信号通路:Bcl-2和白细胞介素-1β转化酶家族蛋白酶抑制剂对糖皮质激素和Fas介导的细胞毒性的不同作用
J Immunol. 1996 Nov 1;157(9):3845-9.
8
The Src-homology domain 2-bearing protein tyrosine phosphatase-1 inhibits antigen receptor-induced apoptosis of activated peripheral T cells.含Src同源结构域2的蛋白酪氨酸磷酸酶-1抑制抗原受体诱导的活化外周T细胞凋亡。
J Immunol. 1999 Jun 1;162(11):6359-67.
9
Overexpression of AML1 renders a T hybridoma resistant to T cell receptor-mediated apoptosis.AML1的过表达使T杂交瘤对T细胞受体介导的凋亡产生抗性。
Oncogene. 1998 Oct 8;17(14):1813-20. doi: 10.1038/sj.onc.1202087.
10
Fas is expressed early in human thymocyte development but does not transmit an apoptotic signal.Fas在人类胸腺细胞发育早期表达,但不传递凋亡信号。
J Immunol. 1999 Aug 1;163(3):1195-204.

引用本文的文献

1
In Vivo Characterization of ONL1204, a Small Peptide Inhibitor of the Fas Receptor, as a Potential Neuroprotective Therapy for Geographic Atrophy and Dry Age-Related Macular Degeneration.Fas受体小分子肽抑制剂ONL1204作为地图样萎缩和干性年龄相关性黄斑变性潜在神经保护疗法的体内特性研究
Biomedicines. 2025 Aug 22;13(9):2052. doi: 10.3390/biomedicines13092052.
2
Neuroinflammation and pathways that contribute to tourette syndrome.神经炎症与导致抽动秽语综合征的途径。
Ital J Pediatr. 2025 Feb 28;51(1):63. doi: 10.1186/s13052-025-01874-3.
3
Targeting γc family cytokines with biologics: current status and future prospects.
使用生物制剂靶向γc家族细胞因子:现状与未来前景
MAbs. 2025 Dec;17(1):2468312. doi: 10.1080/19420862.2025.2468312. Epub 2025 Feb 18.
4
Immune Tolerance Regulation Is Critical to Immune Homeostasis.免疫耐受调节对免疫稳态至关重要。
J Immunol Res. 2025 Jan 7;2025:5006201. doi: 10.1155/jimr/5006201. eCollection 2025.
5
Polymorphisms Influence the Expression of the Fas and FasL Genes in COVID-19.多态性影响新冠病毒病中Fas和FasL基因的表达。
Int J Mol Sci. 2025 Jan 14;26(2):666. doi: 10.3390/ijms26020666.
6
NFAT3-FasL axis synchronously regulates apoptosis and necroptosis in murine cochlear outer hair cells after noise trauma.噪声损伤后,NFAT3-FasL轴同步调节小鼠耳蜗外毛细胞的凋亡和坏死性凋亡。
Front Mol Neurosci. 2024 Jul 15;17:1422646. doi: 10.3389/fnmol.2024.1422646. eCollection 2024.
7
Unlocking Transplant Tolerance with Biomaterials.利用生物材料实现移植耐受
Adv Healthc Mater. 2025 Feb;14(5):e2400965. doi: 10.1002/adhm.202400965. Epub 2024 Jul 3.
8
Apoptotic vesicles are required to repair DNA damage and suppress premature cellular senescence.凋亡小体是修复 DNA 损伤和抑制过早细胞衰老所必需的。
J Extracell Vesicles. 2024 Apr;13(4):e12428. doi: 10.1002/jev2.12428.
9
Molecular and temporal control of restimulation-induced cell death (RICD) in T lymphocytes.T淋巴细胞中再刺激诱导的细胞死亡(RICD)的分子与时间调控
Front Cell Death. 2023;2. doi: 10.3389/fceld.2023.1281137. Epub 2023 Oct 30.
10
Advances in translational research of the rare cancer type adrenocortical carcinoma.罕见癌症类型肾上腺皮质癌的转化研究进展。
Nat Rev Cancer. 2023 Dec;23(12):805-824. doi: 10.1038/s41568-023-00623-0. Epub 2023 Oct 19.